RxDoctor Payments DataLook up a doctor →

Hidenao Kimura, MD

Internal Medicine · Tualatin, ORNPI 1770519340

Payments from drug & device makers

$10,630in general payments, 2019–2025

Across 449 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Amgen$2K
  • Johnson & Johnson$1K
  • Pfizer$741
  • AstraZeneca$652
  • Novo Nordisk$531
  • plus $4K from 31 others

What the payments were for

  • Food & beverage$10,52899%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,630 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$84,550
Medicare patients
66
Services billed
615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$97,049
EliquisApixaban99$75,672
JardianceEmpagliflozin43$63,327
Repatha SureclickEvolocumab23$33,507
TrulicityDulaglutide18$25,833
XareltoRivaroxaban20$21,321
QuliptaAtogepant13$13,765
Atorvastatin Calcium315$5,770
Pulmicort FlexhalerBudesonide12$5,171
Breo ElliptaFluticasone/Vilanterol11$4,651
RestasisCyclosporine11$3,692
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,434
Ezetimibe84$2,255
Omeprazole92$2,148
Lisinopril171$1,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Pulmicort Flexhaler$652$102,21995 claims
PfizerEliquis$741$75,67299 claims
Boehringer IngelheimJardiance$464$63,32743 claims
Lilly USA, LLCTrulicity$1,832$25,83318 claims
Johnson & JohnsonXarelto$1,317$21,32120 claims
AbbVieQulipta, Restasis$388$17,45724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Tualatin

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →